Conjugates for treating diseases caused by PSMA expressing cells
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
1. A conjugate having the formula
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a conjugate having a formula
or a pharmaceutically acceptable salt thereof.
3. The pharmaceutical composition of claim 2 , wherein the conjugate or the pharmaceutically acceptable salt thereof is present in a therapeutically effective amount for treating a disease in a host animal caused by a pathogenic population of cells, said cells expressing prostate-specific membrane antigen (PSMA).
4. The pharmaceutical composition of claim 2 , further comprising one or a plurality of additional therapeutically active compounds.
5. The pharmaceutical composition of claim 2 , further comprising one or a plurality of pharmaceutically acceptable carriers.
6. The pharmaceutical composition of claim 2 , further comprising one or a plurality of pharmaceutically acceptable diluents.
7. The pharmaceutical composition of claim 2 , further comprising one or a plurality of pharmaceutically acceptable excipients.
8. The pharmaceutical composition of claim 2 , further comprising a component selected from the group consisting of an additional therapeutically active compound, a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient, and a combination thereof.
9. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is in bulk form.
10. The pharmaceutical composition of claim 2 , e pharmaceutical composition is a unit dose.